Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.
The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases.
The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College’s Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.
Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.
The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.
“Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy.” said Professor Girgenrath, the study’s corresponding author. “While most MD treatments are single-target therapies, we’re delving into combinations of different therapies to target multiple pathways.”
The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc).
By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
The Latest Bing News on:
Novel Therapy to Treat Muscular Dystrophy
- Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophyon April 29, 2021 at 12:43 am
Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne ...
- Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophyon April 27, 2021 at 10:02 pm
and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data ...
- Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ...on April 27, 2021 at 10:02 pm
Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a ...
- 4basebio UK Societas - Evaluation licence for muscular dystrophy vectoron April 26, 2021 at 11:43 pm
Under the terms of the agreements, the parties will collaborate to develop a Hermes based non-viral vector incorporating a patented full length dystrophin gene with the view to developing a novel ...
- Duchenne Muscular Dystrophy Treatment Market 2021 Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2024on April 22, 2021 at 5:00 pm
treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical RandD to release novel disease therapies, and increasing awareness ...
The Latest Google Headlines on:
Novel Therapy to Treat Muscular Dystrophy
The Latest Bing News on:
- Why Muscular Dystrophy UK decided to transfer a key service to another charityon May 16, 2021 at 4:08 pm
Marcus Brown, trustee at Muscular Dystrophy UK, explains why the charity decided to transfer one of its services to another charity.
- Benefit being held for 3-year-old boy with Duchenne muscular dystrophyon May 15, 2021 at 2:33 am
SHELBY - Colton Reed doesn't know there is anything wrong with him. The 3-year-old son of Shelby High School graduates Rusty and Jordan Reed is afflicted with Duchenne muscular dystrophy, ...
- Decreased YAP activity reduces proliferative ability in human induced pluripotent stem cell of duchenne muscular dystrophy derived cardiomyocyteson May 14, 2021 at 3:16 am
Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration accompanied by dilated cardiomyopathy. Recently, abnormality of yes-associated protein (YAP) has been reported as ...
- Global Limb-Girdle Muscular Dystrophy Markets, Epidemiology and Patient Flow Analysis Report 2021 - ResearchAndMarkets.comon May 14, 2021 at 2:16 am
The "Global Limb-Girdle Muscular Dystrophy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
- Nurses, nonprofits, others take vaccine to homebound peopleon May 12, 2021 at 11:04 pm
For months, Victoria McAllister searched online to make a vaccination appointment. Unlike other people who can hop into a car, though, she has ruptured discs that ...
- Fulcrum : FDA Grants Fast Track Designation To Losmapimod For Potential FSHD Treatmenton May 12, 2021 at 5:07 am
Fulcrum Therapeutics Inc. (FULC) said Wednesday that the U.S. Food and Drug Administration has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular ...
- New gene editing strategies developed for Duchenne muscular dystrophyon May 10, 2021 at 9:00 pm
UT Southwestern scientists successfully employed a new type of gene therapy to treat mice with Duchenne muscular dystrophy (DMD), uniquely utilizing CRISPR-Cas9-based tools to restore a large section ...
- Parent Project Muscular Dystrophy Announces Addition of Nemours' Dr. Mena Scavina to PPMD Staff as Certified Duchenne Care Center Program Advisoron May 6, 2021 at 7:32 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), ...
- Karin Elharrar, MK with muscular dystrophy, to head powerful committeeon May 5, 2021 at 3:10 pm
MK Karin Elharrar uses a wheelchair due to her muscular dystrophy, which has not prevented her from breaking down barriers since getting elected to the Knesset for the first time eight years ago.
- Global Duchenne Muscular Dystrophy Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.comon May 5, 2021 at 2:33 am
The “Global Duchenne Muscular Dystrophy Epidemiology and Patient Flow - 2021” report has been added to ResearchAndMarkets.com’s offering. Global Duchenne Muscular Dystrophy Epidemiology and Patient ...